Ipsen S.A. (IPSEF)

104.91 0.00 (0.00%) As of 12:53PM EDT. Market open.

Ipsen S.A.

65, quai Georges Gorse
Cedex
Boulogne-Billancourt 92650
France
33 1 58 33 50 00
http://www.ipsen.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 5,700

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David Loew	MD, CEO & Director	2.24M	N/A	1967
Mr. Aymeric Le Chatelier	Exec. VP & Group CFO	827.7k	N/A	1969
Dr. Aidan Murphy Ph.D.	Exec. VP of Technical Operations	N/A	N/A	1966
Mr. Craig Marks	Vice-Pres of Investor Relations	N/A	N/A	N/A
Mr. Francois Garnier	Exec. VP of Legal Affairs & Gen. Counsel	N/A	N/A	1962
Ms. Gwenan White	Exec. VP of Communications & Public Affairs	N/A	N/A	N/A
Mr. Regis Mulot	Exec. VP & Chief HR Officer	N/A	N/A	1966
Mr. Stephan Gagne	Head of New Tokyo Office	N/A	N/A	N/A
Ms. Dominique Laymand	Exec. VP of Ethics & Social Responsibility Officer	N/A	N/A	1954
Mr. Benoit Hennion	Exec. VP of Consumer Healthcare	N/A	N/A	1976

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. It offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. It offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.

Corporate governance

Ipsen S.A.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.